Veru Inc VERU
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VERU is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Veru Inc. - VERU
-
VERU INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Veru Inc. - VERU
-
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study
-
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
-
Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023
-
Veru Reports Clinical Data from the Discontinued ARTEST Study of Enobosarm, Novel Selective Androgen Receptor Targeting Agonist, in AR+ ER+ HER2- Metastatic Breast Cancer
-
Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023
-
Veru Shares Hit 52-Week Low After FDA Denies Emergency Use For Covid-19 Treatment
Trading Information
- Previous Close Price
- $1.00
- Day Range
- $0.93–1.00
- 52-Week Range
- $0.66–6.57
- Bid/Ask
- $0.95 / $0.96
- Market Cap
- $85.50 Mil
- Volume/Avg
- 861,451 / 898,536
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 5.20
- Dividend Yield
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers, as well as a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA and others where in maximum revenue is generated from USA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 233
- Website
- https://www.verupharma.com
Valuation
|
Metric
|
VERU
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.46 |
Price/Sales | 5.20 |
Price/Cash Flow | — |
Price/Earnings
VERU
Financial Strength
|
Metric
|
VERU
|
|---|---|
Quick Ratio | 1.08 |
Current Ratio | 1.56 |
Interest Coverage | −39.69 |
Quick Ratio
VERU
Profitability
|
Metric
|
VERU
|
|---|---|
Return on Assets (Normalized) | −103.51% |
Return on Equity (Normalized) | −189.69% |
Return on Invested Capital (Normalized) | −143.71% |
Return on Assets
VERU
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ysmy | $450.9 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gwftpj | $89.4 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Zktnmx | $87.3 Bil | |
SGEN
| Seagen Inc Ordinary Shares | Gfztybw | $40.4 Bil | |
MRNA
| Moderna Inc | Gpz | $29.8 Bil | |
ARGX
| argenx SE ADR | Htsw | $26.4 Bil | |
BNTX
| BioNTech SE ADR | Lnpwt | $23.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gfvfpfv | $20.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Gqhhzx | $16.5 Bil | |
INCY
| Incyte Corp | Zwhgzd | $11.8 Bil |